ArticleFrontiers in cellular and infection microbiology2025
Time trends in the burden of non-COVID-19 lower respiratory tract infections among children aged 0 to 14 years.
Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Machine learning-driven risk assessment of severeFrontiers in medicine · 2026Article
- Development and Validation of a Nomogram Model to Predict the Risk of Severe Pneumonia in Children with Pneumococcal Infection.Infection and drug resistance · 2026Article
- Burden of lower respiratory infections in five East Asian countries from 1990 to 2021: observation, comparison, and forecast from the global burden of disease study 2021.Frontiers in public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to analyze the global burden, temporal trends, and main pathogenic characteristics of pediatric lower respiratory tract infections(LRTIs) across different age groups. Methods: This repeated cross-sectional study included children with LRTIs aged 0-14 years from 204 countries and regions from 1990 to 2021. The primary outcomes were cases and rates of incidence, disability-adjusted life years (DALYs), mortality, and their trends associated with LRTIs. Estimates were generated using the DisMod-MR 2.1 tool. Results: In 2021, neonates had the highest incidence and mortality. From 1990 to 2021, the global mortality rate of LRTIs in children decreased by 76.8%, with the reduction primarily driven by a 79.1% decrease in children aged 2-4 years. However, in low-middle SDI regions, the mortality rate remained as high as 4502.003 per 100,000. The primary pathogens contributing to LRTI-related DALYs and deaths in most age groups were Conclusions: The burden of LRTIs remains significant in low- and middle-income countries, as well as among neonates and females. While the burden of various pathogens is gradually declining, influenza warrants particular attention. Expanding vaccine coverage, improving sanitary conditions, and early interventions for high-risk children are crucial strategies to reduce LRTI burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.